节点文献

乐铂单药治疗乳腺癌的Ⅱ期临床研究

A Phase Ⅱ Clinical Trial of Lobaplatin as a Single Agent in the Treatment of Breast Cancer

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 姜文奇; 林桐榆; 徐瑞华; 管忠震;

【Author】 Jiang Wenqi,Lin Tongyu,Xu Ruihua,et al(Cancer Center,Sun Yat-sen University of Medical Sciences,Guangzhou 510060)

【机构】 中山医科大学肿瘤医院内科;

【摘要】 为了观察和评价乐铂单药治疗恶性肿瘤的疗效和毒副反应,1994年6月至1996年10月,应用单药乐铂治疗复发性或转移性的乳腺癌病人42例,乐铂50mg/m2,静脉滴注,每3周1个疗程,平均治疗2个疗程。结果,CR1例,PR18例,有效率45.2%。乐铂的毒性反应主要为骨髓毒性,特别是血小板减少,Ⅲ~Ⅳ级占14.5%,为其剂量限制性毒性;其它常见的不良反应为胃肠道反应(Ⅰ~Ⅱ级);乐铂的肾毒性和神经毒性不明显。

【Abstract】 To evaluate the effect and adverse events of lobaplatin to treat breast cancer,from June 1994 to October 1996,42 patients with histologically proven breast cancer received single agent therapy by lobaplatin 50 mg/m 2 iv drop,repeat 3 weeks.Average 2 cycles were given for each patient.Out of 42 breast cancer,1 CR, 18 PR were observed.The response rate was 45.2%.The main dose limiting toxicity of lobaplatin was myelotoxisity especially thrombocytopenia.The other adverse events were slight and no obvious and nephrotoxisity neurotoxisity were observed.

【关键词】 乐铂; 肿瘤; 化学治疗;
【Key words】 Loboplatin Breast tumour Chemotherapy;
  • 【文献出处】 实用癌症杂志 ,THE PRACTICAL JOURNAL OF CANCER , 编辑部邮箱 ,1998年04期
  • 【分类号】R737.9
  • 【被引频次】51
  • 【下载频次】132
节点文献中: 

本文链接的文献网络图示:

本文的引文网络